Craft
  • Home
  •  / Jounce Therapeutics
Jounce Therapeutics

Jounce Therapeutics

Market Capitalization

$145 M

2022-09-22

Jounce Therapeutics Summary

Company summary

Overview
Jounce Therapeutics is a clinical-stage immunotherapy company. It develops cancer treatment therapies. It provides the translational science platform that identifies biomarkers to match the right therapy.
Type
Public
Founded
2013
HQ
Cambridge, MA, US | view all locations
Website
http://jouncetx.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Stephen Farrand

    Stephen Farrand, Chief Technical Officer

  • Richard Murray

    Richard Murray, Chief Executive Officer and President

  • Robert Kamen
  • Elizabeth Trehu

    Elizabeth Trehu, Chief Medical Officer

LocationsView all

1 location detected

  • Cambridge, MA HQ

    United States

    780 Memorial Dr

Jounce Therapeutics Financials

Summary financials

Net income (Q2, 2022)
($33.5M)
Cash (Q2, 2022)
$77.7M
EBIT (Q2, 2022)
($33.7M)
Enterprise value
$79.2M

Footer menu